Welcome to our dedicated page for Celldex Therapeutics news (Ticker: CLDX), a resource for investors and traders seeking the latest updates and insights on Celldex Therapeutics stock.
Celldex Therapeutics Inc. (NASDAQ: CLDX) is a clinical-stage biotechnology company developing antibody-based therapies for mast cell-driven inflammatory and allergic diseases. This page provides centralized access to official press releases, financial disclosures, and third-party analysis of CLDX's progress in advancing treatments for chronic urticarias, atopic dermatitis, and other high-need conditions.
Investors and researchers will find timely updates on clinical trial milestones, regulatory submissions, and strategic collaborations. Content spans Phase 1-3 study results, peer-reviewed research highlights, and management commentary from earnings calls. All materials are sourced directly from Celldex or reputable financial/medical publications.
Key focus areas include developments for lead candidate barzolvolimab (anti-KIT antibody), bispecific antibody CDX-622, and pipeline expansion into new indications. Bookmark this page to monitor progress in mast cell biology innovation without promotional bias.
Celldex Therapeutics (NASDAQ:CLDX) has launched its global Phase 3 program for barzolvolimab in Chronic Spontaneous Urticaria (CSU) patients. The program includes two trials, EMBARQ-CSU1 and EMBARQ-CSU2, enrolling over 1,800 patients who remain symptomatic despite antihistamine or biologic treatments. Barzolvolimab, a novel monoclonal antibody, targets the root cause of CSU by blocking the KIT receptor, essential for mast cell function. The trials will evaluate two dosing regimens against placebo over 52 weeks, with the primary endpoint assessing reduction in urticaria activity at Week 12. This advancement follows successful Phase 2 results, where barzolvolimab demonstrated rapid, durable, and clinically meaningful responses in moderate to severe CSU patients.
Celldex Therapeutics (NASDAQ: CLDX) announced its participation in the Jefferies Healthcare Conference. The management will engage in a fireside chat on June 6, 2024, at 10:00 am ET. A webcast of the presentation will be available on the Celldex website under the 'Events & Presentations' section. The session will be accessible for replay for 90 days after the event.
Celldex Therapeutics (NASDAQ:CLDX) announced significant improvements in angioedema in patients with chronic spontaneous urticaria (CSU) during a Phase 2 trial of barzolvolimab. Data revealed a rapid onset of relief within 2 weeks, sustained through 12 weeks, across various dose groups. The study included 208 participants and demonstrated clinically meaningful and statistically significant advancements in AAS7 scores, with improvements seen in patients regardless of their prior omalizumab status. The 300 mg cohort showed the highest efficacy, with a 25.32 LS mean difference from placebo. The findings, presented at the EAACI Congress 2024, suggest barzolvolimab could become an effective treatment for CSU, leading to the initiation of Phase 3 studies this summer.
Celldex Therapeutics announced the dosing of the first patient in its Phase 2 study of barzolvolimab for treating prurigo nodularis (PN). This humanized monoclonal antibody targets the KIT receptor tyrosine kinase, important for mast cell function, believed to drive chronic itch and neuroinflammation in PN. Earlier Phase 1b results showed significant clinical benefits with barzolvolimab, prompting this larger, double-blind, placebo-controlled study. The trial will assess the efficacy and safety of two dosing regimens in about 120 patients over 40 weeks, aiming to evaluate itch improvement and lesion healing. The study involves 50 global centers, including the U.S.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) reported Q1 2024 financial results and a corporate update. Phase 3 CSU studies to start in summer 2024. Positive Phase 2 CSU 12-week data presented at AAAAI 2024, with 52-week data to follow later. Phase 2 CIndU study enrollment completed, with Phase 2 PN study ongoing. Atopic dermatitis selected for Phase 2 study by YE 2024. Cash position at $823.8 million. Total revenue at $0.2 million. R&D expenses at $31.7 million. G&A expenses at $9.1 million. Net loss at $32.8 million.
FAQ
What is the current stock price of Celldex Therapeutics (CLDX)?
What is the market cap of Celldex Therapeutics (CLDX)?
